epinastine has been researched along with Active Hyperemia in 3 studies
epinastine: RN given refers parent cpd
epinastine : A benzazepine that is 6,11-dihydro-5H-dibenzo[b,e]azepine in which the azepine ring is fused to the e side of 4,5-dihydro-1H-imidazol-2-amine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epinastine is effective and safe for the treatment of allergic conjunctivitis." | 9.19 | Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. ( Fujishima, H; Ohashi, Y; Takamura, E, 2014) |
| "Epinastine is effective and safe for the treatment of allergic conjunctivitis." | 5.19 | Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. ( Fujishima, H; Ohashi, Y; Takamura, E, 2014) |
| "Signs of allergic conjunctivitis generally were reduced most by a combination of a CC in combination with ATs or EH." | 2.79 | Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. ( Bilkhu, PS; Kennedy, R; Naroo, SA; Robertson, L; Wolffsohn, JS, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Eli, H | 1 |
| Solomon, A | 1 |
| Bilkhu, PS | 1 |
| Wolffsohn, JS | 1 |
| Naroo, SA | 1 |
| Robertson, L | 1 |
| Kennedy, R | 1 |
| Fujishima, H | 1 |
| Ohashi, Y | 1 |
| Takamura, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-masked, Comparison Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study -[NCT01363700] | Phase 3 | 87 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean palpebral and bulbar conjunctiva hyperemia was assessed by the investigator at 5, 10, and 20 min post challenge and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe). Total hyperemia score is defined as the sum of the palpebral and bulbar conjunctiva scores.~The endpoint used the average score of three time points (5, 10, and 20 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 7 (5, 10, and 20 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 2.4 |
| Olopatadine Ophthalmic Solution | 2.7 |
| Placebo Ophthalmic Solution | 3.7 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean palpebral and bulbar conjunctiva hyperemia was assessed by the investigator at 5, 10, and 20 min post challenge and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe). Total hyperemia score is defined as the sum of the palpebral and bulbar conjunctiva scores. Count unit was defined each eye.~The endpoint used the average score of three time points (5, 10, and 20 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 5 (5, 10, and 20 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 2.7 |
| Placebo Ophthalmic Solution | 4.1 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean ocular itching score was assessed by the subject at 3, 5, and 10 min post challenge on a 5 points scale of 0-4 where 0=no itching and 4=incapacitating itch.~The endpoint used the average score of three time points (3, 5, and 10 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 7 (3, 5, and 10 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 0.2 |
| Olopatadine Ophthalmic Solution | 0.2 |
| Placebo Ophthalmic Solution | 1.5 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean ocular itching score was assessed by the subject at 3, 5, and 10 min post challenge and graded on a 5 points scale of 0-4 where 0=no itching and 4=incapacitating itch. Count unit was defined each eye.~The endpoint used the average score of three time points (3, 5, and 10 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 5 (3, 5, and 10 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 0.4 |
| Placebo Ophthalmic Solution | 1.7 |
1 review available for epinastine and Active Hyperemia
| Article | Year |
|---|---|
Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends.
Topics: Administration, Ophthalmic; Anti-Allergic Agents; Benzazepines; Conjunctivitis, Allergic; Cromolyn S | 2018 |
2 trials available for epinastine and Active Hyperemia
| Article | Year |
|---|---|
Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis.
Topics: Acute Disease; Adult; Aged; Allergens; Combined Modality Therapy; Conjunctiva; Conjunctivitis, Aller | 2014 |
Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Topics: Adult; Allergens; Anti-Allergic Agents; Cedrus; Conjunctiva; Conjunctivitis, Allergic; Dibenzazepine | 2014 |